Halozyme Therapeutics Q3 Adjusted Earnings, Revenue Rise; 2026 Guidance Lifted

MT newswire2026/11/05 20:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:50 PM EST, 11/05/2026 (MT Newswires) -- Halozyme Therapeutics (HALO) reported Q3 adjusted earnings late Thursday of $2.39 per diluted share, compared with $1.72 a year earlier. Analysts polled by FactSet expected $2.30. Revenue in the three months ended Sept. 30 was $493 million, compared with $354.3 million a year earlier. Analysts projected $491.6 million. The company said it expects 2026 adjusted earnings in the range of $8.75 to $9.05, compared with its previous guidance of $8.65 to $9.00. Analysts expect $8.62. Revenue for the full year is slated to be between $1.86 billion to $1.93 billion, compared with $1.84 billion to $1.91 billion previously. Analysts expect $1.88 billion.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.

华尔街见闻•2026/11/07 07:31